Perioperative Pembrolizumab Expands in Bladder Cancer

The indication now crosses the cisplatin divide

The July 10, 2026, approval covers enfortumab vedotin combined with either pembrolizumab or the fixed combination of pembrolizumab and berahyaluronidase alfa-pmph. Treatment is given before radical cystectomy and continued afterward, making this a perioperative regimen rather than an exclusively neoadjuvant or adjuvant intervention.

The practical change is the eligible population. Earlier perioperative use of enfortumab vedotin plus pembrolizumab centered on patients considered unable to receive cisplatin. The expanded indication includes cisplatin-eligible adults as well, provided they have muscle-invasive bladder cancer and are candidates for radical cystectomy.

That distinction matters because cisplatin eligibility has traditionally organized systemic treatment planning before surgery. Renal function, hearing, neuropathy, cardiac status and performance status are commonly considered when determining whether a patient can receive cisplatin-based combination chemotherapy. The new indication does not make those assessments irrelevant, but it means they no longer determine whether the antibody–drug conjugate and checkpoint inhibitor combination is available under the federal label.

The approval is not an indication for every person with bladder cancer. It does not automatically encompass non–muscle-invasive disease, unresectable or metastatic disease under this perioperative indication, patients who are not candidates for cystectomy, or those pursuing a bladder-preserving strategy. Those settings require separate evidence and treatment frameworks.

Evidence came from a randomized perioperative comparison

The expansion into the cisplatin-eligible population was evaluated in KEYNOTE-B15/EV-304, an open-label, randomized phase 3 trial registered as NCT04700124. The registry lists an enrollment target of 784 participants with muscle-invasive bladder cancer who were eligible for radical cystectomy and cisplatin-based chemotherapy.

Participants were assigned to perioperative enfortumab vedotin plus pembrolizumab or the established approach of neoadjuvant gemcitabine plus cisplatin followed by radical cystectomy. The experimental strategy therefore had to be assessed against active curative-intent chemotherapy, not against surgery alone.

The study’s primary outcomes included event-free survival and pathologic complete response. Event-free survival captures clinically consequential events occurring across the perioperative course, while pathologic complete response measures the absence of residual invasive cancer in the cystectomy specimen. The FDA concluded that the trial supported expanding the indication to the cisplatin-eligible population.

The FDA approval notice is the controlling source for the agency’s efficacy estimates, confidence intervals, follow-up and safety findings. A verified numerical extract of those results was not included with the source record supplied for this explainer, so effect sizes are not reconstructed from secondary reporting or inferred from the trial registry. The registry describes the protocol and planned enrollment but is not a substitute for the FDA’s analyzed dataset.

The regulatory expansion complements evidence from KEYNOTE-905/EV-303, registered as NCT03924895, which studied perioperative enfortumab vedotin plus pembrolizumab in patients who were ineligible for cisplatin. Taken together, the programs address both sides of the historical cisplatin-eligibility divide, producing the broader cystectomy-eligible indication.

Planning now starts with regimen selection, not access alone

For multidisciplinary teams, the decision is no longer simply whether a patient qualifies for cisplatin. In cisplatin-eligible disease, clinicians must now compare two active perioperative pathways: the newly approved enfortumab vedotin–pembrolizumab strategy and cisplatin-based neoadjuvant chemotherapy, while accounting for the exact populations and treatment sequences tested.

The comparison should include more than tumor response. Enfortumab vedotin is associated with clinically important risks including peripheral neuropathy, skin reactions, hyperglycemia and ocular toxicity. Pembrolizumab can cause immune-mediated toxicities involving multiple organs. Cisplatin-based chemotherapy has a different burden, including nephrotoxicity, ototoxicity, neuropathy, myelosuppression and nausea.

Baseline comorbidity can therefore favor or disfavor either approach even when both are permitted by the label.

Timing also matters. A perioperative regimen creates obligations on both sides of surgery. Teams need to coordinate systemic therapy, restaging, operative scheduling, recovery and the decision to resume postoperative treatment. Toxicity before cystectomy may affect readiness for surgery, while complications or delayed recovery may affect delivery of the adjuvant component.

The approval of pembrolizumab and berahyaluronidase alfa-pmph provides a subcutaneous pembrolizumab-containing option within the authorized combination. It should be understood as an alternative formulation named in the indication, not as a different anticancer partner or evidence that the perioperative course can be shortened. Administration and dosing should follow the approved prescribing information.

Shared planning remains essential. Urologic oncology, medical oncology, pathology, radiology and perioperative care teams should establish the intended sequence before treatment starts and preserve the curative role of timely radical cystectomy. An FDA approval expands available choices; it does not establish that one pathway is best for every eligible patient.

Important uncertainties remain

Open-label treatment can influence some aspects of care and adverse-event reporting, although central pathology review and time-to-event definitions can reduce bias for key outcomes. Generalizability also depends on how closely routine patients resemble trial participants who were fit enough for radical cystectomy and, in the expansion trial, eligible for cisplatin.

Pathologic complete response is informative but is not by itself equivalent to cure. Event-free and overall survival, longer follow-up, late toxicity and postoperative treatment completion are important for judging the durability and full clinical value of a perioperative regimen.

The trial comparison also does not answer every current sequencing question. It does not establish how the combination should be used with bladder-preserving chemoradiation, how to manage patients who cannot proceed to cystectomy after neoadjuvant treatment, or whether selected patients can safely omit postoperative therapy. Those decisions should not be inferred from the expanded label.

Cost, infusion or injection capacity, toxicity monitoring and access to coordinated surgical care will shape implementation. Policymakers and health systems should also distinguish broader regulatory eligibility from equitable delivery: expanding a label does not by itself remove geographic, insurance or specialty-care barriers.

Questions clinicians ask

Does this approval replace neoadjuvant cisplatin-based chemotherapy?

No. It adds a perioperative enfortumab vedotin–pembrolizumab option for cisplatin-eligible patients rather than withdrawing cisplatin-based treatment. Selection should reflect the randomized comparison, contraindications, toxicity profiles, surgical timing and the patient’s informed preferences.

Must a patient be cisplatin-ineligible to receive the combination?

Not under the expanded indication. The FDA decision extends the neoadjuvant–adjuvant combination to adults with muscle-invasive bladder cancer who are eligible for radical cystectomy regardless of cisplatin eligibility, while preserving the need to confirm that the disease and intended surgical pathway fit the label.

Can the regimen be used if cystectomy is not planned?

This approval is tied to a perioperative strategy built around radical cystectomy. It should not be extrapolated automatically to definitive bladder-preserving chemoradiation, patients medically unable to undergo surgery, or treatment in which cystectomy is intentionally omitted.

Is subcutaneous pembrolizumab a separate efficacy strategy?

No. Pembrolizumab and berahyaluronidase alfa-pmph is an authorized formulation of pembrolizumab used with enfortumab vedotin. Its inclusion expands administration options but does not change the need to follow the approved perioperative sequence, safety precautions and prescribing information.

References

1. FDA approves pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph, each with enfortumab vedotin — U.S. Food and Drug Administration, 2026
2. Study of Perioperative Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Muscle-Invasive Bladder Cancer — ClinicalTrials.gov, 2021
3. Study of Perioperative Pembrolizumab With or Without Enfortumab Vedotin in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer — ClinicalTrials.gov, 2019
4. Bladder Cancer Treatment (PDQ®)–Health Professional Version — National Cancer Institute, 2026